NSTEMI Admission Orders
Admit all NSTEMI patients to a monitored unit with continuous cardiac rhythm monitoring, initiate dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor (preferably ticagrelor or prasugrel), start parenteral anticoagulation, and obtain serial high-sensitivity troponins with ECG monitoring. 1, 2
Immediate Admission Requirements
Monitoring and Location
- Admit to monitored unit (CCU/step-down) with continuous telemetry 1
- Continue rhythm monitoring minimum 24 hours or until PCI, whichever comes first, for low-risk patients 1
- Extend monitoring beyond 24 hours for patients at increased arrhythmia risk 1
Diagnostic Testing on Admission
ECG:
- Obtain 12-lead ECG immediately
- Repeat ECG with any recurrent symptoms or if initial diagnosis uncertain 1
- Consider additional leads (V3R, V4R, V7-V9) if standard leads inconclusive and ongoing ischemia suspected 1
Cardiac Biomarkers:
- Serial high-sensitivity troponin measurements using 0h/1h algorithm (preferred) or 0h/2h algorithm 1
- If first two measurements inconclusive but clinical suspicion remains high, obtain additional testing at 3 hours 1
- Continue serial troponins for prognostic stratification 1
Echocardiography:
- Order transthoracic echo to evaluate LV function, regional wall motion abnormalities, and exclude differential diagnoses 1
- Perform immediately if hemodynamic instability or cardiac arrest 1
Antiplatelet Therapy Orders
Aspirin (for all patients without contraindications)
- Loading dose: 150-300 mg PO (or 75-250 mg IV) 1
- Maintenance: 75-100 mg daily (use 81 mg daily if combined with ticagrelor) 1, 2
P2Y12 Inhibitor (choose one based on patient factors)
First-line options:
Ticagrelor (preferred for most patients, regardless of invasive vs conservative strategy):
Prasugrel (for P2Y12-naïve patients proceeding to PCI):
- Loading: 60 mg PO
- Maintenance: 10 mg daily (reduce to 5 mg daily if age ≥75 years or weight <60 kg)
- Continue for 12 months 1
Clopidogrel (only if prasugrel/ticagrelor unavailable, not tolerated, or contraindicated):
- Loading: 300-600 mg PO
- Maintenance: 75 mg daily 1
Critical caveat: Do NOT routinely pre-treat with P2Y12 inhibitor if coronary anatomy unknown and early invasive management planned 1
Anticoagulation Orders (choose one)
Parenteral anticoagulation required for all patients in addition to antiplatelet therapy 1, 2
Preferred options:
Enoxaparin: 1 mg/kg SC every 12 hours (reduce to 1 mg/kg once daily if CrCl <30 mL/min); may give 30 mg IV loading dose; continue until PCI or hospital discharge 2
Fondaparinux: 2.5 mg SC daily; continue until PCI or discharge 2
- Must add UFH or bivalirudin during PCI to prevent catheter thrombosis 2
UFH: 60 IU/kg IV bolus (max 4000 IU), then 12 IU/kg/hour infusion (max 1000 IU/hour); adjust per aPTT per hospital protocol; continue 48 hours or until PCI 2
Bivalirudin: 0.10 mg/kg loading dose, then 0.25 mg/kg/hour (only for early invasive strategy); continue until angiography/PCI 2
Additional Admission Orders
Anti-ischemic Therapy
- Nitroglycerin sublingual 0.4 mg PRN chest pain (hold if systolic BP <90 mmHg)
- Consider IV nitroglycerin if ongoing ischemia
- Beta-blocker (if no contraindications): metoprolol 25-50 mg PO every 6-12 hours or equivalent
- High-intensity statin: atorvastatin 80 mg daily or rosuvastatin 40 mg daily
Supportive Care
- Oxygen only if SpO2 <90% (avoid routine supplemental oxygen)
- NPO after midnight if early invasive strategy planned
- IV access with normal saline at KVO rate
- Strict bed rest initially, then progressive activity as tolerated
Laboratory Orders
- Complete metabolic panel, CBC, lipid panel, HbA1c
- Type and screen
- BNP or NT-proBNP for risk stratification (optional but reasonable)
Contraindications to Note
Do NOT order:
- GP IIb/IIIa inhibitors routinely (only consider for high-risk features during PCI) 1, 2
- IV fibrinolytic therapy (Class III Harm) 2
- Additional biomarkers beyond hs-troponin for routine diagnosis (h-FABP, copeptin) 1
Risk Stratification for Timing of Angiography
Determine urgency of invasive strategy based on clinical presentation:
- Urgent/immediate (<2 hours): Refractory angina, hemodynamic instability, electrical instability, cardiogenic shock
- **Early invasive (<24 hours):** High-risk features (elevated troponin, dynamic ECG changes, GRACE score >140)
- Ischemia-guided (selective): Low-risk patients without high-risk features
The 2021 ESC guidelines 1 and 2014 AHA/ACC guidelines 2 provide the framework for these admission orders, with emphasis on immediate dual antiplatelet therapy, anticoagulation, and monitored setting to reduce mortality and recurrent ischemic events.